New York, United States
OnCusp Therapeutics is a promising player in the biopharmaceutical industry, founded in 2021 with headquarters in the United States. Their mission, elegantly encapsulated in their slogan, "We Bring Oncology Innovation to Life," reflects a dedication to evolving preclinical discoveries into validated cancer treatments.
The company thrives under the leadership of co-founders Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu. OnCusp has assembled a team with deep experience in biotech startups and global partnership creation, paving the way for strategic advancement in oncology assets.
Recently, OnCusp secured a significant $100.00M Series A investment on 01 January 2024, attracting a diverse group of prominent investors, including Novo Holdings, Blackbird Ventures, and F-Prime Capital, among others. This underscores investor confidence and positions OnCusp for impactful growth and innovation in the highly competitive biotechnology, health care, and pharmaceutical sectors.
Imescia